Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Receivables (2023 - 2025)

BioScience Health Innovations (BHIC) has disclosed Receivables for 3 consecutive years, with $536975.0 as the latest value for Q4 2025.

  • Quarterly Receivables rose 339.84% to $536975.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $536975.0 through Dec 2025, up 339.84% year-over-year, with the annual reading at $536975.0 for FY2025, 339.84% up from the prior year.
  • Receivables for Q4 2025 was $536975.0 at BioScience Health Innovations, up from $63212.0 in the prior quarter.
  • The five-year high for Receivables was $536975.0 in Q4 2025, with the low at $3849.0 in Q1 2023.
  • Average Receivables over 3 years is $113461.7, with a median of $34180.5 recorded in 2023.
  • The sharpest move saw Receivables surged 70.51% in 2024, then soared 1311.56% in 2025.
  • Over 3 years, Receivables stood at $36448.0 in 2023, then soared by 234.95% to $122083.0 in 2024, then surged by 339.84% to $536975.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $536975.0, $63212.0, and $390013.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.